CTOR
Citius Oncology Inc (CTOR)
Healthcare • NASDAQ • $0.91+0.65%
Key Fundamentals
- Symbol
- CTOR
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Price
- $0.91
- Daily Change
- +0.65%
- Market Cap
- $80.05M
- Trailing P/E
- N/A
- Forward P/E
- N/A
- 52W High
- $6.19
- 52W Low
- $0.49
- Analyst Target
- $6.00
- Dividend Yield
- N/A
- Beta
- 3.57
About Citius Oncology Inc
Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. is a subsidiary of Leonard-Meron Biosciences, Inc.
Research CTOR on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.